EvolutionaryScale vs Profluent (2026)
The two protein language model labs with the strongest publication records, descended from different research lineages, and both have done the thing this category usually skips: submitted the method to peer review at the highest level. EvolutionaryScale came out of the group that built the first transformer language model for proteins and its flagship model reasons over sequence, structure and function together. Profluent came out of the project that first demonstrated language models could generate functional proteins. The differentiators are access and governance. EvolutionaryScale offers the widest access routes in this category including holding the weights yourself, and publishes the most substantive position anywhere here on the biosecurity risk that designing novel proteins creates. Profluent is more legible commercially, with three named routes from licensing a molecule to platform access, and has not addressed the biosecurity question equivalently.
- The models are published at the highest level, with the flagship model appearing in a major peer reviewed journal, so the method has passed external review rather than a demonstration.
- The widest access in this category and the only route where a user can hold the weights, which changes the dependency entirely for an organisation that cannot rely on a vendor remaining available.
- The strongest governance disclosure located in this category, addressing the specific biosecurity risk that protein design creates rather than publishing generic principles.
- Peer reviewed twice at the highest level and specific about architecture, with the foundational demonstration that language models can generate functional proteins published in a major journal.
- Molecular evidence is unusually direct, including designed systems validated experimentally rather than only benchmarked computationally.
- Three access routes are named openly, from licensing a designed molecule through to platform access, which makes the commercial structure legible even without a published price.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. EvolutionaryScale and Profluent are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | EvolutionaryScale | Profluent |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | Not recorded | 2022 |
| Headquarters | New York, NY | Emeryville, CA |
| Website | evolutionaryscale.ai | profluent.bio |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards EvolutionaryScale its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and AI Governance and Bias Disclosure. Set against Profluent, EvolutionaryScale grades higher on AI Governance and Bias Disclosure, EHR and Interoperability Depth and Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Profluent its top capability grade on AI Centrality, Model and Technology Transparency and Setting and Specialty Coverage. Set against EvolutionaryScale, Profluent does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose EvolutionaryScale or Profluent?
The AI Health Index grades EvolutionaryScale higher than Profluent on every axis that separates them, AI Governance and Bias Disclosure, EHR and Interoperability Depth and Deployment Model and Data Residency. Profluent does not grade higher on any scored axis.
Where do EvolutionaryScale and Profluent differ most?
The widest separation the AI Health Index records between EvolutionaryScale and Profluent is on AI Governance and Bias Disclosure, where EvolutionaryScale grades A and Profluent grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do EvolutionaryScale and Profluent grade the same?
The AI Health Index grades EvolutionaryScale and Profluent the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both companies design proteins that do not exist in nature, which is the one place in this index where the governance question is biosecurity rather than bias. EvolutionaryScale publishes a substantive position on that risk; Profluent's disclosure gap on it is specific and consequential and should be raised directly in any evaluation. Neither holds a located security attestation or trust centre.
Molecular evidence and clinical evidence are different things on both records: excellent laboratory validation exists and no therapeutic from either has been established in humans, so neither should be evaluated as a clinical stage proposition.